- 作者：Sangchoon Jeon ; John T. Walkup ; Douglas W. Woods ; Alan Peterson ; John Piacentini ; Sabine Wilhelm ; Lily Katsovich ; Joseph F. McGuire ; James Dziura ; Lawrence Scahill
- 关键词：Tourette syndrome ; Yale Global Tic Severity Scale ; Clinical Global Impression ; Cognitive behavioral intervention ; Signal detection analysis ; Mixture model
- 刊名：Contemporary Clinical Trials
- 出版年：November, 2013
- 年：2013
- 卷：36
- 期：2
- 页码：414-420
- 全文大小：438 K
Objective
To compare three statistical strategies for classifying positive treatment response based on a dimensional measure (Yale Global Tic Severity Scale [YGTSS]) and a categorical measure (Clinical Global Impression鈥擨mprovement [CGI-I] scale).Method
Subjects (N = 232; 69.4% male; ages 9-69 years) with Tourette syndrome or chronic tic disorder participated in one of two 10-week, randomized controlled trials comparing behavioral treatment to supportive therapy. The YGTSS and CGI-I were rated by clinicians blind to treatment assignment. We examined the percent reduction in the YGTSS-Total Tic Score (TTS) against Much Improved or Very Much Improved on the CGI-I, computed a signal detection analysis (SDA) and built a mixture model to classify dimensional response based on the change in the YGTSS-TTS.
Results
A 25% decrease on the YGTSS-TTS predicted positive response on the CGI-I during the trial. The SDA showed that a 25% reduction in the YGTSS-TTS provided optimal sensitivity (87%) and specificity (84%) for predicting positive response. Using a mixture model without consideration of the CGI-I, the dimensional response was defined by 23% (or greater) reduction on the YGTSS-TTS. The odds ratio (OR) of positive response (OR = 5.68, 95% CI = [2.99, 10.78]) on the CGI-I for behavioral intervention was greater than the dimensional response (OR = 2.86, 95% CI = [1.65, 4.99]).
Conclusion
A 25% reduction on the YGTSS-TTS is highly predictive of positive response by all three analytic methods. For trained raters, however, tic severity alone does not drive the classification of positive response.
Clinicaltrials.gov identifiers: ; .